252 related articles for article (PubMed ID: 11173815)
21. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs.
Yin JX; Wei Z; Xu JJ; Sun ZQ
Cancer Chemother Pharmacol; 2015 Sep; 76(3):525-36. PubMed ID: 26183605
[TBL] [Abstract][Full Text] [Related]
22. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
23. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system.
Nishiyama N; Kato Y; Sugiyama Y; Kataoka K
Pharm Res; 2001 Jul; 18(7):1035-41. PubMed ID: 11496942
[TBL] [Abstract][Full Text] [Related]
25. Relationship between age and nephrotoxicity following single low-dose cisplatin (CDDP) injection in rats.
Namikawa K; Kinsoku A; Minami T; Okazaki Y; Kadota E; Teramura K; Hashimoto S
Biol Pharm Bull; 1995 Jul; 18(7):957-62. PubMed ID: 7581250
[TBL] [Abstract][Full Text] [Related]
26. Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
Hosoda A; Matsumoto Y; Toriyama Y; Tsuji T; Yoshida Y; Masamichi S; Kohno T
Biol Pharm Bull; 2020; 43(9):1331-1337. PubMed ID: 32879207
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
28. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Leone R; Fracasso ME; Soresi E; Cimino G; Tedeschi M; Castoldi D; Monzani V; Colombi L; Usari T; Bernareggi A
Cancer Chemother Pharmacol; 1992; 29(5):385-90. PubMed ID: 1312907
[TBL] [Abstract][Full Text] [Related]
29. Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats.
Saad SY; Najjar TA
Arch Toxicol; 2005 Sep; 79(9):493-9. PubMed ID: 15940472
[TBL] [Abstract][Full Text] [Related]
30. Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats.
Ormond PM; Basinger MA; Jones MM; Hande KR
J Pharmacol Exp Ther; 1992 Jul; 262(1):246-51. PubMed ID: 1385629
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
32. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
33. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.
Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N
Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
35. [Preventive effect of urinastatin on cisplatin induced nephrotoxicity in rabbits].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):328-32. PubMed ID: 2567322
[TBL] [Abstract][Full Text] [Related]
36. Early onset of cisplatin-induced nephrotoxicity in streptozotocin-diabetic rats treated with insulin.
Sarangarajan R; Cacini W
Basic Clin Pharmacol Toxicol; 2004 Aug; 95(2):66-71. PubMed ID: 15379782
[TBL] [Abstract][Full Text] [Related]
37. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats.
Nematbakhsh M; Ashrafi F; Safari T; Talebi A; Nasri H; Mortazavi M; Khazaei M; Baradaran-Mahdavi MM
J Nephrol; 2012; 25(3):410-7. PubMed ID: 21928232
[TBL] [Abstract][Full Text] [Related]
38. Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
Hanada K; Mukasa Y; Nomizo Y; Ogata H
J Pharm Pharmacol; 2000 Dec; 52(12):1483-90. PubMed ID: 11197076
[TBL] [Abstract][Full Text] [Related]
39. Reduced renal accumulation and toxicity of cisplatin in experimental galactosemia.
Cacini W; Harden EA; Skau KA
Proc Soc Exp Biol Med; 1993 Jul; 203(3):348-53. PubMed ID: 8516346
[TBL] [Abstract][Full Text] [Related]
40. Renal accumulation and urinary excretion of cisplatin in diabetic rats.
Valentovic MA; Scott LA; Madan E; Yokel RA
Toxicology; 1991; 70(2):151-62. PubMed ID: 1763412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
